FDA Approves First Paediatric Inhaled Insulin
June 10, 2026
The FDA has recently expanded approval for Afrezza (insulin human) Inhalation Powder to include children and adolescents aged 6 years and older.
This ultra-rapid-acting mealtime insulin is delivered directly into the bloodstream through the lungs using a small, breath-powered, pocket-sized inhaler.
A Quality-of-Life Shift: As the first needle-free insulin option for pediatric patients, it aims to eliminate the psychological burden and pain of daily injections.
Rapid Action: The dry powder is absorbed instantly, working within minutes of inhalation to match post-meal blood sugar rises and clearing the body quickly.
Trial Success: The Phase 3 INHALE-1 clinical trial (Haller, 2025) across 38 endocrinology practices proved the inhaled powder provides safe, comparable blood sugar control (HbA1c) to traditional injections.
Higher Satisfaction: The study reported significantly higher treatment satisfaction scores among both young patients and their primary caregivers.
Targeting Mealtime: This tool does not fully replace background, long-acting (basal) insulin injections or baseline pumps, which are still required daily.
Replacing Extra Needles: The inhaler steps in to replace the 3 to 4 rapid-acting injections typically needed for breakfasts, lunches, dinners, and snacks.
Real-Time Dosing: Because it can be taken exactly as the first bite of food is swallowed, families gain the flexibility to dose based on actual food intake rather than pre-meal guessing.
Discreet Care: The small, highly portable inhaler allows older children to confidently manage mealtime insulin at the lunch table, reducing school-day disruptions.
Erratic Schedule Flexibility: The quick onset accommodates unpredictable childhood schedules, growth spurts, and sudden active play.
Blood Sugar Monitoring: Families must continue tracking levels using traditional finger-pricks or continuous glucose monitors (CGMs) to manage standard hypoglycemia risks.
Breathing Requirements: Patients must undergo a simple baseline breathing test (spirometry) before prescription; the drug is strictly contraindicated for children with chronic asthma.
Mild Side Effects: The most common mild adjustments noted during clinical trials included a temporary cough or a scratchy sore throat.
Full Details: To read the complete regulatory details and clinical background, view the official FDA Expanded Approval Statement.
